Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

IL-18 Paradox in Pancreatic Carcinoma: Elevated Serum Levels of Free IL-18 are Correlated With Poor Survival

IL-18 Paradox in Pancreatic Carcinoma: Elevated Serum Levels of Free IL-18 are Correlated With... Downloaded from http://journals.lww.com/immunotherapy-journal by BhDMf5ePHKbH4TTImqenVA5KvPVPZ0P5BEgU+IUTEfzO/GUWifn2IfwcEVVH9SSn on 06/10/2020 CLINICAL STUDY IL-18 Paradox in Pancreatic Carcinoma: Elevated Serum Levels of Free IL-18 are Correlated With Poor Survival Anna Carbone,* Barbara Vizio,* Anna Novarino,w Francesco Angelo Mauri,z Massimo Geuna,y Carlo Robino,J Gabriele Brondino,* Adriana Prati,* Alice Giacobino,w Donata Campra,z Roberto Chiarle,# Gian Ruggero Fronda,z Libero Ciuffreda,w and Graziella Bellone* he survival rate for patients with pancreatic adenocar- Summary: The role of the proinflammatory interleukin (IL)-18 in Tcinoma is among the poorest of all cancers. Lack of cancer progression remains controversial; we thus examined the effective early detection, the high rate of metastases and the hypothesis that impaired antitumor immune response in pancreatic generally refractory response to available treatments con- carcinoma patients is related to elevated levels of its natural tribute to this poor prognosis. The dearth of conventional inhibitor IL-18 binding protein (BP) and/or to alteration in the therapeutic options has, in recent years, motivated the IL-18 receptor complex expression and function. IL-18 and search for immunotherapeutic approaches to pancreatic IL-18 binding protein isoform a (BPa) was assessed in pancreatic 1,2 cancer. carcinoma patients at various disease stages, and after surgery/ It is now clear that both local characteristics of the chemotherapy; http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Journal of Immunotherapy Wolters Kluwer Health

Loading next page...
 
/lp/wolters-kluwer-health/il-18-paradox-in-pancreatic-carcinoma-elevated-serum-levels-of-free-il-0I0R3Jy7KG

References

References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.

Publisher
Wolters Kluwer Health
ISSN
1524-9557
eISSN
1537-4513
DOI
10.1097/CJI.0b013e3181b29168
Publisher site
See Article on Publisher Site

Abstract

Downloaded from http://journals.lww.com/immunotherapy-journal by BhDMf5ePHKbH4TTImqenVA5KvPVPZ0P5BEgU+IUTEfzO/GUWifn2IfwcEVVH9SSn on 06/10/2020 CLINICAL STUDY IL-18 Paradox in Pancreatic Carcinoma: Elevated Serum Levels of Free IL-18 are Correlated With Poor Survival Anna Carbone,* Barbara Vizio,* Anna Novarino,w Francesco Angelo Mauri,z Massimo Geuna,y Carlo Robino,J Gabriele Brondino,* Adriana Prati,* Alice Giacobino,w Donata Campra,z Roberto Chiarle,# Gian Ruggero Fronda,z Libero Ciuffreda,w and Graziella Bellone* he survival rate for patients with pancreatic adenocar- Summary: The role of the proinflammatory interleukin (IL)-18 in Tcinoma is among the poorest of all cancers. Lack of cancer progression remains controversial; we thus examined the effective early detection, the high rate of metastases and the hypothesis that impaired antitumor immune response in pancreatic generally refractory response to available treatments con- carcinoma patients is related to elevated levels of its natural tribute to this poor prognosis. The dearth of conventional inhibitor IL-18 binding protein (BP) and/or to alteration in the therapeutic options has, in recent years, motivated the IL-18 receptor complex expression and function. IL-18 and search for immunotherapeutic approaches to pancreatic IL-18 binding protein isoform a (BPa) was assessed in pancreatic 1,2 cancer. carcinoma patients at various disease stages, and after surgery/ It is now clear that both local characteristics of the chemotherapy;

Journal

Journal of ImmunotherapyWolters Kluwer Health

Published: Nov 1, 2009

There are no references for this article.